Abstract

Purposes : To investigate the evidence for a threshold in the cancer dose-response curve. Materials and methods : Japanese atomic bomb survivor cancer mortality data, based on follow-up to 1990, was used, taking account of random errors in DS86 dose estimates. Results : For all solid cancers analysed together, there is a significant positive dose response (two-sided p 0.05) if all survivors who received 0.5Sv are considered, but the significance vanishes if doses of 0.2 Sv are considered; the same is also true for leukaemia. For solid cancer mortality there is no indication of curvilinearity in the dose response: no statistically significant improvement in fit to a linear relative risk model is provided by addition of quadratic or threshold dose terms. If a relative risk model with a threshold (the dose response is assumed linear above the threshold) is fitted to solid cancer mortality data, the best estimate of the threshold is 0.00 Sv (95% CI 0.00-0.13). If a linearquadratic-threshold model is used the best estimate of the threshold is 0.00 Sv (95% CI 0.00-0.15). For leukaemia mortality there is highly statistically significant upward curvature in the dose response. In particular, if a relative risk model with a threshold (the dose response is assumed linear above the threshold) is fitted to the leukaemia data, the best estimate of the threshold is 0.16Sv (95% CI 0.05-0.40) (twosided p 0.001 for test of departure of threshold from 0). However, there is no evidence for a threshold effect (two-sided p 0.16) when a quadratic term is included in the dose response: the best estimate of threshold in this case is 0.09Sv (95% CI 0.00-0.29). Moreover, addition of a quadratic term improves the fit of a linear-threshold model at borderline levels of statistical significance (two-sided p 0.07). Therefore, the most parsimonious description of the leukaemia dose response is provided by a linear-quadratic function of dose. Conclusions : There is no evidence of threshold-type departures from the linear-quadratic dose response either for solid tumours or for leukaemia in the Japanese atomic bomb survivor mortality data.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.